Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
CG Oncology, Inc. ( (CGON) ) has shared an announcement.
On November 22, 2025, CG Oncology, Inc. announced the appointment of Christina Rossi to its Board of Directors, effective November 24, 2025. Rossi will serve as a Class II director with a term expiring at the 2026 annual meeting of stockholders, receiving a $45,000 annual fee and stock options. Concurrently, Simone Song resigned from the Board, effective immediately, with no disagreements cited with the company.
The most recent analyst rating on (CGON) stock is a Buy with a $55.00 price target. To see the full list of analyst forecasts on CG Oncology, Inc. stock, see the CGON Stock Forecast page.
Spark’s Take on CGON Stock
According to Spark, TipRanks’ AI Analyst, CGON is a Neutral.
CG Oncology, Inc. is currently facing significant financial challenges, with no revenue and ongoing losses. The technical indicators suggest a bearish trend, and the valuation metrics highlight the company’s lack of profitability. The strong equity base and cash reserves provide some stability, but the overall outlook remains cautious due to the reliance on external funding and the need for revenue generation.
To see Spark’s full report on CGON stock, click here.
More about CG Oncology, Inc.
CG Oncology, Inc. operates in the biotechnology industry, focusing on developing innovative therapies for cancer treatment.
Average Trading Volume: 1,009,920
Technical Sentiment Signal: Buy
Current Market Cap: $3.51B
For a thorough assessment of CGON stock, go to TipRanks’ Stock Analysis page.